Role of antibodies in protection elicited by active vaccination with genetically inactivated alpha hemolysin in a mouse model of Staphylococcus aureus skin and soft tissue infections

Clinical and Vaccine Immunology

Volumn 21, Issue 5, 2014, Pages 622-627

  Mocca, Christopher P ^a   Brady, Rebecca A ^a   Burns, Drusilla L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HEMOLYSIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY; STAPHYLOCOCCUS VACCINE; BACTERIAL TOXIN; HEMOLYSIN; MUTANT PROTEIN; RECOMBINANT VACCINE; STAPHYLOCOCCAL ALPHA-TOXIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BACTERIAL COLONIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MIXTURE; GENE INACTIVATION; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SOFT TISSUE INFECTION; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS INFECTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; FEMALE; HEMOLYSIN PROTEINS; MALE; MICE, INBRED BALB C; MUTANT PROTEINS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCAL VACCINES; VACCINES, SYNTHETIC;

EID: 84899753422     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00051-14     Document Type: Article

References (29)

1. Gorwitz RJ, Kruszon-Moran D, McAllister SK, McQuillan G, McDougal LK, Fosheim GE, Jensen BJ, Killgore G, Tenover FC, Kuehnert MJ. 2008. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J. Infect. Dis. 197:1226-1234. http://dx.doi.org/10.1086/ 533494. (Pubitemid 351632753)
2. Lowy FD. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339:520-532. http://dx.doi.org/10.1056/NEJM199808203390806.
3. Foster TJ. 2005. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3:948-958. http://dx.doi.org/10.1038/nrmicro1289. (Pubitemid 43078158)
4. Nygaard TK, DeLeo FR, Voyich JM. 2008. Community-associated methicillin-resistant Staphylococcus aureus skin infections: advances toward identifying the key virulence factors. Curr. Opin. Infect. Dis. 21:147-152. http://dx.doi.org/10.1097/QCO.0b013e3282f64819. (Pubitemid 351641517)
5. Chambers HF, Deleo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7:629-641. http://dx.doi.org/10. 1038/nrmicro2200.
6. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA, EMERGEncy ID Net Study Group. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674. http://dx.doi.org/10.1056/NEJMoa055356.
7. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. 2003. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120. http://dx.doi.org/10.1128/JCM.41.11. 5113-5120.2003. (Pubitemid 37429924)
8. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Michael JR, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292. http://dx.doi.org/10.1093/cid/cir034.
9. van Hal SJ, Fowler VG, Jr. 2013. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin. Infect. Dis. 56:1779-1788. http://dx.doi.org/10.1093/cid/cit178.
10. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136. http://dx.doi.org/10.1093/jac/40.1.135. (Pubitemid 27341646)
11. Askari E, Tabatabai SM, Arianpoor A, Nasab MN. 2013. VanA-positive vancomycin-resistant Staphylococcus aureus: systematic search and review of reported cases. Infect. Dis. Clin. Pract. 21:91-93. http://dx.doi.org/10.1097/ IPC.0b013e31826e8199.
12. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis. 202:1050-1058. http://dx.doi.org/10.1086/656043.
13. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M. 2009. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 106:5883-5888. http://dx.doi.org/10.1073/pnas.0900743106.
14. Berube BJ, Bubeck Wardenburg J. 2013. Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel) 5:1140-1166. http://dx.doi.org/10.3390/toxins5061140.
15. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR. 2012. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin. Vaccine Immunol. 19:377-385. http://dx.doi.org/10.1128/CVI. 05589-11.
16. Ohlsen K, Lorenz U. 2010. Immunotherapeutic strategies to combat staphylococcal infections. Int. J. Med. Microbiol. 300:402-410. http://dx.doi.org/10.1016/j.ijmm.2010.04.015.
17. Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17:1055-1065. http://dx.doi.org/10.1128/CVI.00131-10.
18. Menzies BE, Kernodle DS. 1994. Site-directed mutagenesis of the alpha-toxin gene of Staphylococcus aureus: role of histidines in toxin activity in vitro and in a murine model. Infect. Immun. 62:1843-1847. (Pubitemid 24136985)
19. Menzies BE, Kernodle DS. 1996. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect. Immun. 64:1839-1841. (Pubitemid 26129845)
20. Brady RA, Mocca CP, Prabhakara R, Plaut RD, Shirtliff ME, Merkel TJ, Burns DL. 2013. Evaluation of genetically inactivated alpha toxin for protection in multiple mouse models of Staphylococcus aureus infection. PLoS One 8:e63040. http://dx.doi.org/10.1371/journal.pone.0063040.
21. Plaut RD, Mocca CP, Prabhakara R, Merkel TJ, Stibitz S. 2013. Stably luminescent Staphylococcus aureus clinical strains for use in bioluminescent imaging. PLoS One 8:e59232. http://dx.doi.org/10.1371/journal.pone.0059232.
22. Adhikari RP, Karauzum H, Sarwar J, Abaandou L, Mahmoudieh M, Boroun AR, Vu H, Nguyen T, Devi VS, Shulenin S, Warfield KL, Aman MJ. 2012. Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia. PLoS One 7:e38567. http://dx.doi.org/10.1371/ journal.pone.0038567.
23. Prabhakara R, Foreman O, De Pascalis R, Lee GM, Plaut RD, Kim SY, Stibitz S, Elkins KL, Merkel TJ. 2013. Epicutaneous model of community-acquired Staphylococcus aureus skin infections. Infect. Immun. 81:1306-1315. http://dx.doi.org/10.1128/IAI.01304-12.
24. Chen J, Trounstine M, Alt FW, Young F, Kurahara C, Loring JF, Huszar D. 1993. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int. Immunol. 5:647-656. http://dx.doi.org/ 10.1093/intimm/5.6.647. (Pubitemid 23209419)
25. Verdrengh M, Tarkowski A. 1997. Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect. Immun. 65:2517-2521. (Pubitemid 27264071)
26. Rigby KM, DeLeo FR. 2012. Neutrophils in innate host defense against Staphylococcus aureus infections. Semin. Immunopathol. 34:237-259. http://dx.doi.org/10.1007/s00281-011-0295-3.
27. Kim MH, Granick JL, Kwok C, Walker NJ, Borjesson DL, Curry FR, Miller LS, Simon SI. 2011. Neutrophil survival and c-kit(+)-progenitor proliferation in Staphylococcus aureus-infected skin wounds promote resolution. Blood 117:3343-3352. http://dx.doi.org/10.1182/blood-2010-07-296970.
28. Mölne L, Verdrengh M, Tarkowski A. 2000. Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect. Immun. 68: 6162-6167. http://dx.doi.org/10.1128/IAI.68.11.6162-6167.2000.
29. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. 2013. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin. Infect. Dis. 56:1554-1561. http://dx.doi.org/10.1093/cid/cit123.